IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: ideayabio.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/8/2024 | $50.00 | Outperform | Mizuho |
3/8/2024 | $55.00 | Buy | BTIG Research |
8/8/2023 | $33.00 | Outperform | SVB Securities |
5/24/2023 | $32.00 | Buy | Goldman |
4/24/2023 | $18.00 → $24.00 | Hold → Buy | Stifel |
3/23/2023 | $26.00 | Buy | Berenberg |
2/28/2023 | $25.00 | Outperform | RBC Capital Mkts |
12/28/2022 | $29.00 | Overweight | CapitalOne |
10/27/2022 | $26.00 | Buy | Citigroup |
8/15/2022 | $16.00 → $13.00 | Buy → Hold | Stifel |
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 34,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Morgan Stanley 22nd Annual Global Healthcare ConferenceWednesday, September 4th, 2024 at 5:35 PM ET Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Judah Frommer, Executive Director, Senior Equity Research AnalystA live audio webcast of the conference event, as p
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 19, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 150,000 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule
Darovasertib achieves triple-digit enrollment in Phase 2/3 trial in 1L HLA-A2*02:01(-) MUM; and >50 patients enrolled in Phase 2 neoadjuvant UM studyASCO 2024 oral presentation of darovasertib in neoadjuvant UM; FDA Type C meeting for neoadjuvant UM in Q3'24 and targeting Phase 2 neoadjuvant UM data update in H2'24Demonstrated preliminary proof-of-concept for IDE397 in MTAP urothelial and lung cancer; 1 PR awaiting confirmation has confirmed and 1 additional PR still awaiting confirmation, from the 2 uPRs noted in the July 8, 2024 webcastIDEAYA, in consultation with Amgen, has now financially budgeted to support its obligations for target IDE397 / AMG 193 clinical combination expansion in NS
Option for an exclusive worldwide license for potential first-in class B7H3/PTK7 topo-I-payload bispecific antibody drug conjugate (BsADC) programB7H3/PTK7 co-expression found in multiple solid tumor types, including double-digit percent prevalence in lung, colorectal, and head and neck cancersRational combo opportunities with IDEAYA's DNA Damage Repair (DDR) pipeline, including IDE161 (PARG)Targeting development candidate nomination in H2 2024SOUTH SAN FRANCISCO, Calif. and BEIJING, China, July 31, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that it has enter
SOUTH SAN FRANCISCO, Calif., July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. 2024 BTIG Virtual Biotechnology ConferenceMonday, August 5th, 2024 at 10:00 AM ET Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research AnalystA live audio webcast of the conference event will be available through the conference host. About IDE
SOUTH SAN FRANCISCO, Calif., July 11, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced the closing of its underwritten public offering of 8,355,714 shares of its common stock at a public offering price of $35.00 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 285,715 shares of common stock at a public offering price of $34.9999 per pre-funded warrant, before underwriting discounts and commissions. This includes the exercise in full by the underwriters of their option to purchase up to an additional 1,127,142 shares of common stock in the offering. The gross proceeds from the offering, before deducting underwriting disco
SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 7,228,572 shares of common stock and pre-funded warrants to purchase 285,715 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $35.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $34.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, IDEAYA has granted the underwriters a 30
SOUTH SAN FRANCISCO, Calif., July 9, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) today announced that it intends to offer and sell up to $200.0 million of shares of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase its common stock in an underwritten public offering. In addition, IDEAYA intends to grant the underwriters a 30-day option to purchase up to $30.0 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)
S-8 - IDEAYA Biosciences, Inc. (0001676725) (Filer)
10-Q - IDEAYA Biosciences, Inc. (0001676725) (Filer)
10-Q/A - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
424B5 - IDEAYA Biosciences, Inc. (0001676725) (Filer)
424B5 - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)
Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & CompanySOUTH SAN FRANCISCO, Calif., May 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Daniel A. Simon, will join the company as its Chief Business Officer in August 2024. "We are thrilled to welcome Daniel to IDEAYA Biosciences. His extensive expertise in corporate strategy
- Dr. Karlene Cimprich, Ph.D. (Stanford University), is a leading scientist in replication stress mechanisms and regulation of DNA Damage Repair pathways - Dr. Kornelia Polyak, M.D., Ph.D. (DFCI, Harvard University) is a renowned physician-scientist focused on breast cancer clinical management and tumor biology SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Dr. Karlene Cimprich, Ph.D., and Dr. Kornelia Polyak, M.D., Ph.D., to its Scientific Advisory Board.
Former Senior Vice President and Head of Early Oncology Development and Clinical Research at Pfizer will lead IDEAYA's clinical development efforts as Chief Medical OfficerOver twenty-five years of experience in clinical development and translational research, including at leading pharmaceutical companies and major research institutionsSOUTH SAN FRANCISCO, Calif., Nov. 28, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Darrin M. Beaupre, M.D., Ph.D., has joined the company as its Chief Medical Officer, effective November 21, 2022.
- Dr. Mackey formerly served as Senior Vice President of Pfizer Worldwide Research and Development and as Director of Pfizer's La Jolla Laboratories SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors. Dr. Mackey brings over 30 years of life sciences research, development and operational experience to IDEAYA. As Senior
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Frank McCormick, Ph.D., FRS, to Chair of the IDEAYA Scientific Advisory Board. Dr. McCormick is a Professor at the University of California at San Francisco's (UCSF) Helen Diller Family Comprehensive Cancer Center and holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Prior to joining UCSF,
SOUTH SAN FRANCISCO, Oct. 18, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced that Michael White, Ph.D., will join the company as its Chief Scientific Officer, effective November 1, 2021. "We are thrilled to welcome Dr. White, and we believe his deep industry experience as CSO and Head of Tumor Biology at Pfizer, and extensive knowledge in cancer biology developed during a prolific academic career at UT Southwestern, wil
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Susan Kelley, M.D., to its Board of Directors. Dr. Kelley brings over 25 years of experience in oncology drug research and development to IDEAYA. Most recently she served as Chief Medical Officer of the Multiple Myeloma Research Consortium (MMRC) where she led the strategic design and management of clinical trials in North America. Prior to the MMRC, she held positions of increasing responsibility at Bayer Healthcare Pharmaceutica
SOUTH SAN FRANCISCO, Calif., Feb. 8, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the effectiveness of the Investigational New Drug (IND) application for a Phase 1 clinical trial to evaluate IDE397, a potential best-in-class methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE397 is IDEAYA's most advanced synthetic lethality program, and being developed in the clinic for cancer patients harboring methylthioadenosine phosphorylase (MTAP) deletion, which is prevalent in approximately 15% of all solid tumors. IDEAYA is target
~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-
Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational trial in Q2 2023 in First-Line HLA-A2 negative MUM, with median PFS as primary endpoint for potential accelerated approvalConfirmed overall response rate (ORR) of 30%, disease control rate (DCR) of 87% and median PFS of ~7 months in 63 evaluable Any-Line MUM patientsConfirmed overall response rate (ORR) of 35%, disease control rate (DCR) of 100% and median PFS of ~11 months in 20 evaluable Hepatic-Only MUM patientsHistorical % ORR and median PFS by other therapies in MUM have been low, rang
Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patientsTumor shrinkage observed in 31 of 35 (89%) Any-Line MUM patientsMedian PFS not yet reached and >5 months in evaluable First-Line MUM patients; observed median PFS of ~5 months in evaluable Any-Line MUM patientsHistorical % ORR and median PFS by other therapies in MUM have been low, ranging from ~0% to 5% ORR and ~2 to 3 months median PFSProof-of-concept for use in (neo)adjuvant UM with tumor shrinkage in 5 of 5 ocular lesions, including reductions of ~-74% and -67%, each with improved visual symptomsTotal UM and MUM annual incidence in
SAN FRANCISCO, May 3, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in May 2022. 2022 JP Morgan Conference Call SeriesMonday, May 16 at 10:00am ETFireside chat with Yujiro Hata, Chief Executive Officer, IDEAYA Biosciences, hosted by Anupam Rama, Managing Director US SMID Biotechnology Equity Research Virtual Guggenheim Synthetic Lethality Day Monday, May 16 at 12:00pm ETFireside
Observed preclinical complete suppression (~95-100%) of tumor SDMA in multiple MTAP-deleted patient derived xenograft (PDX) models across indications Interim IDE397 clinical data demonstrates robust plasma pharmacodynamic modulation, exceeding target of >60% reduction of plasma SAM across all evaluated cohorts Observed clinical exposure-dependent reduction of tumor pharmacodynamic biomarker SDMA in target tumor types, including 95% reduction of tumor SDMA No drug-related Serious Adverse Events (SAEs) observed through Cohort 5 Enrolling into Cohort 6 of the dose escalation Phase 1 evaluating IDE397; have not yet determined the maximum tolerated dose (MTD) through Cohort 5 Targeting initiation
SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced plans to issue a pre-market press release and host an Investor Webcast on Tuesday, March 15, 2022 to discuss interim clinical data for IDE397, a potential best-in-class MAT2A inhibitor being evaluated in a Phase 1 Clinical Trial (NCT 04794699) in patients having tumors with MTAP deletion. IDEAYA will host a conference call and webcast
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients. "The partial responses, percentage of patients with tumor shrinkage and disease control rate observed from the darovasertib and crizotinib synthetic lethal combination in heavily pr
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma (MUM) (ClinicalTrials.gov Identifier: NCT03947385).
Mizuho initiated coverage of IDEAYA Biosciences with a rating of Outperform and set a new price target of $50.00
BTIG Research initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $55.00
SVB Securities initiated coverage of IDEAYA Biosciences with a rating of Outperform and set a new price target of $33.00
Goldman initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $32.00
Stifel upgraded IDEAYA Biosciences from Hold to Buy and set a new price target of $24.00 from $18.00 previously
Berenberg initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $26.00
RBC Capital Mkts initiated coverage of IDEAYA Biosciences with a rating of Outperform and set a new price target of $25.00
CapitalOne initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $29.00
Citigroup initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $26.00
Stifel downgraded IDEAYA Biosciences from Buy to Hold and set a new price target of $13.00 from $16.00 previously
JP Morgan analyst Anupam Rama maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and raises the price target from $65 to $69.
RBC Capital analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $53 to $61.
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55 per share. SeaStar Medical shares dipped 34% to $8.55 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) shares jumped 139% to $2.78 after the company announced results for a Swine Model pilot study for Probudur. Kazia Therapeutics Limited (NASDAQ:KZIA) gained 129% to $0.4325 after the company announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday. Shares of Kura Sushi USA, Inc. (NASDAQ:KRUS) fell sharply in today's pre-market trading after the company posted downbeat results for its third quarter on Tuesday. Kura Sushi reported quarterly earnings of $0.00 per share which missed the analyst consensus estimate of $0.01. The company reported quarterly sales of $63.082 million which missed the analyst consensus estimate of $63.101 million, according to data from Benzinga Pro. Indivior shares fell 4.2% to $56.00 in the pre-market trading session. Here are some big stocks recording losses in today's pre-market trading sess
IDEAYA is selling 7,228,572 shares of common stock and pre-funded warrants to purchase 285,715 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $35.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $34.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,127,142 shares of its common stock at the public offering price per share, before underwriting discounts and commissions.
BTIG analyst Justin Zelin maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $55 to $62.
Stifel analyst Benjamin Burnett maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and maintains $63 price target.